Avandia (rosiglitazone) increases the risk of heart attack
June 2007
Patients are asking about the news that Avandia (rosiglitazone) increases the risk of heart attack.
A new meta-analysis suggests a higher risk of heart attacks in patients taking Avandia compared to other meds or placebo.
Experts crunching the same numbers come up with differing conclusions and point out the study's shortcomings. The complicated statistics are explored in our Detail-Document.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote